The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...
Civic Science on MSN17h
GLP-1 Trends by CivicScience: Current Users Report Shifts in Retail Shopping and Alcohol Consumption, Plus More InsightsThis is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...
These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...
Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...
Dean has Radio 1's Early Breakfast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback